Daily Programme

Friday, 31 October 2014


Symposia Sessions

The following Symposia sessions will take place on Friday 31 October 2014.

Please click here to download all symposia as one PDF.

Title of symposium




Friday, 31 October 2014 - 08:00 - 10:00

19. The Union/CDC Late breaker session (TBC) TBC TBC 112
20. Community-driven psychosocial support: don't forget medication counselling! TB/ Nurses and Allied Professionals Niranjan Konduri (USA), 
Antonia Kwiecien (USA)
21. Practical considerations for successful contact tracing and linkage to care in low- and middle-income countries Tuberculosis E Jane Carter (USA), 
Anna Mandalakas (USA)
22. Countries' experience in decentralising PMDT: community-based MDR-/XDR-TB care Tuberculosis Agnes Gebhard (Netherlands), 
Alexander Golubkov (USA)
23. QMS implementation and accreditation of TB laboratories TB/Bacteriology and Immunology Stella van Beers (Netherlands), Heidemarie Albert (South Africa) 114
24. Mathematical approaches to better understand and tackle tuberculosis Tuberculosis Cris Vilaplana (Spain), 
Pere-Joan Cardona (Spain)
25. Tobacco control, trade and international treaties Tobacco Pranay Lal (India) 116
26. Know your epidemic: fundamental to solutions for child TB Adult and Child Lung Health Steve M Graham (Australia) 118/119
27. What practical steps are needed to achieve a patient-centered continuum of care in TB control? Civil Society Virginia Williams (Switzerland), 
Sara Massaut (Netherlands)

Friday, 31 October 2014 - 14:30- 16:30

28. Adolescent TB, TB-HIV and MDR-TB: addressing a vulnerable population with unique needs using innovative Adult and Child Lung Health Lisa Nelson (Switzerland) 112
29. Management of latent tuberculosis infection: from evidence to policy Tuberculosis Alberto Matteelli (Italy), 
Andreas Sandgren (Sweden)
30. TB in Europe: MDR-/XDR-TB control and challenges of high risk groups Tuberculosis Dominik Zenner (UK), 
Andrei Dadu (Moldova)
31. Implementing "FAST": a re-focused approach to institutional TB transmission control Tuberculosis Edward Nardell (USA) 113
32. Changing the status quo in TB drug and regimen R&D Tuberculosis Grania Brigden (France) 114
33. TB patients: learning from the experience of those personally affected Civil Society Victoria Garland (USA), 
Jenniffer Dietrich (Switzerland)
34. Supervision or support? A debate panel on challenges around DOT and patient-centered care TB/ Nurses and Allied Professionals Tiemi Arakawa (Brazil) 116
35. Biosafety for TB laboratories: involving local professional associations in practical sustainable approaches TB/Bacteriology and Immunology Maureen Ellis (Canada) 118/119
36. Tobacco, poverty and possible solutions: health promotion funding models Tobacco Kayleigh Bleymann (UK), 
Jonathan Romo (Mexico)

Abstract Sessions


Session Section(s) Chair(s)
Friday, 31 October 2014 - (10:15-11:15)    
2. Multi disciplinary approach to TB control    Tuberculosis  Temitope Adepoyibi (USA)





Friday, 31 October 2014, 12:45-14:15



11. Drug monitoring and adverse events


Siva Danaviah (South Africa), Ivan Solovic (Slovakia)

12. Finding cases: how good are our notification systems? TB      James Mpunga (Malawi), Lukas Fenner (Switzerland) 

13. Epidemiology: where is TB? Hotspots, hospitals and the highlands of Mexico


Alberto Colorado (Mexico),Luis Cuevas (UK)

14. TB control strategies: what is effective? TB Stacie Stender (South Africa), Einar Heldal (Norway)

15. Lessons learnt from implementating Xpert MTB/RIF


Heidi Albert (South Africa), Christopher Gilpin (Switzerland)

16. The depths of drinking, drugs and depression in TB TB

Adam Karpati (USA), Alice Christensen (Tanzania)

17. Prophylactic therapies


Carol Nawina Nyirenda (Zambia), Mamodikoe Makhene (USA)

18. MDR-TB management: new approaches TB Lucy Chesire (Kenya), Nora Rachel Mira (Philippines)
19. TB drug treatment regimens/trials TB Andrey Borisov (USA), Jacob Creswell (Switzerland)

 20. Best practices in patient adherence and support


Virginia Williams (Switzerland),TBC


Session Section(s) Chair(s)
Friday, 31 October 2014, 10:15-11:15    
23. TB in children: outcomes, extra pulmonary TB, BCG and other ACLH Elisabetta Walters (South Africa)
24. COPD and outcomes post-TB ACLH TBC
25. Asthma, spirometry adn ARIs ACLH Jean-William Fitting (Switzerland)
26. Xpert MTB/RIF: implementation and performance BACT. Sanne Van Kampen (Netherlands)
27. External quality assurance for TB: getting better all the time! BACT. Stella Van Beers (Netherlands)
28. Culture and phenotypic drug susceptibility testing BACT. Rumina Hasan (Pakistan)
29. AFB smear microscopy BACT. Thomas Shinnick (USA)
30. What do singers, football and maps have in common: new horizons in TB community engagement CS Wim Vandevelde (South Africa)
31. Inextricably linked: integrating TB and HIV care HIV Erica Lessem (USA)
32. Best practices in supporting clients to complete TB treatment NAPS Marian Loveday (South Africa)
33. Tuberculosis and diabetes: look out for both TB Jean-Pierre Zellweger (Switzerland)
34. TB in special populations TB Roberto Assael (Mexico)
35. Social determinants and quality of TB care TB Latha Rajan (USA)
36. Comorbidity and deadly TB TB Shu-Hua Wang (USA)
37. TB active case finding TB Lovett Lawson (Nigeria)
38. Tuberculosis: a contact sport TB  Ya Diul Mukadi (USA)
39. MDR-TB: outcomes of treatment TB Zohar Mor (Israel)
40. MDR-TB management TB Valérie Schwoebel (France)
41. Case-finding: special interventions TB Nunurai Ruswa (Namibia)
42. A potpourri of TB issues TB Ronald Ncube (Zimbabwe)
43. Bidis, Bloomberg, Bali and Behaviour: frontiers in tobacco control TC Anne Jones (USA)
44. David vs Goliath: fighting the media war against the tobacco industry TC Elangovan Vidhubala (India)

Plenary Sessions

Friday, 31 October 2014

Time: 11:30 - 12:30  Room: Auditorium

"Past and future examples of community engagement"

Speaker: Mark Dybul, Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

"Robert Koch Lecture on TB vaccines development"

Chair: Pere-Joan Cardona (Spain)

Speaker: Stefan H E Kaufmann, Founding Director and Managing Director of the Max Planck Institute for Infection Biology in Berlin, Germany


  Mark Dybul (Switzerland)


Dr Mark Dybul is the Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria. Dybul has worked on HIV and public health for more than 25 years as a clinician, scientist, teacher and administrator.

A graduate of Georgetown Medical School, he joined the National Institute of Allergy and Infectious Diseases, where he conducted HIV research, including the first randomised, controlled clinical trial with combination antiretroviral therapy in Africa. He was a driving force behind the creation of the President’s Emergency Plan for AIDS Relief (PEPFAR) and became its leader as US Global AIDS Coordinator from 2006 to 2009. He went on to serve as co-director of the Global Health Law Program at Georgetown, where he was also a Distinguished Scholar. In 2012 he was appointed to his current position as Executive Director of The Global Fund.

  Stefan H E Kaufmann (Germany)


Prof Stefan H E Kaufmann is the Founding Director and Managing Director of the Max Planck Institute  for Infection Biology in Berlin, where he heads the Department of Immunology. He is also Professor for Microbiology and Immunology at Charité University Clinics Berlin.

Author of more than 700 papers, Prof Kaufmann’s current scientific interests focus on immunity to bacterial pathogens with emphasis on tuberculosis and rational vaccine and biomarker design. He is the co-developer of a recombinant BCG vaccine candidate, which is in a phase II clinical trial, and the coordinator of several other international and interdisciplinary projects. His professional activities have ranged from serving as an Alternate Board Member for the GAVI Alliance and editorship more than 20 scientific journals to participation in numerous professional societies and initiation of the Day of Immunology, which raises awareness of the importance of immunology to health and well-being.

Sponsored Satellite Symposia

 Title of Sessions                       


Organised by  

Friday, 31 October 2014 - 17:00 - 18:30

07. The pediatric TB drug market: Progress and future direction                                         Adult & Child Lung Health TB Alliance & UNITAID
08. The Sustainable OR capacity building initiative in Ethiopia, CORE and MORE for TB Tuberculosis USAID TB CARE I/ KNCV Tuberculosis Foundation 
09. Responding to MDR-TB from the ground up: case studies on community-driven solutions Tuberculosis The Lilly MDR-TB Partnership

Union Administrative Meetings





Scientific Programme Committee Meeting


Side Meetings

Friday , 31 October 2014 


Time: 17:00-18:30 

Room: 127/128

To bring together a group of ICT and health experts from across the globe to discuss the role of ICT in healthcare in India, with a focus on TB treatment adherence.  The meeting will be hosted by the National Forum on Tuberculosis, India. 

ChairDalbir Singh 


(Meeting open to all delegates)

Time: 17:30-20:30

Room: 122/123

This facilitated TB IC consultation will engage the panel, composed of country representatives and TB IC experts, and the audience in a discussion on the best TBIC practices currently being implemented in-country, the TB IC tools currently being used and available for adaptation, and the best practices in scaling-up TBIC activities, including healthcare worker surveillance.

A summary report from this consultation will be prepared and provided to the sponsors and other governmental entities involved in global TB prevention and control.

Background: TB infection control (TBIC) is an important but neglected aspect of TB prevention, diagnosis and treatment. Absence of effective TBIC has led to outbreaks of drug-susceptible and drug-resistant TB in inpatient and outpatient settings causing unnecessary and preventable morbidity and mortality among patients and health care workers (HCWs). HCWs are exposed to TB in their work place settings and have a higher incidence of TB than the general population.

HIV infected individuals are more vulnerable to TB when their cellular immune systems decline, both because they reactivate latent TB and because they progress rapidly from infection to disease when exposed. The nosocomial transmission of multi-drug resistant (MDR) and extensively drug resistant (XDR) TB among persons ill with AIDS in hospitals and congregate settings has resulted in extremely high case fatality rates.

Coordinator: Susan A. Maloney, MD, MHSc; Global TB Coordinator, Office of the Director, Center for Global Health, US Centers for Disease Control and Prevention

Region Meetings




Friday, 31 October 2014

10:15-11:15 South-East Asia Region 113
Africa Region 114
Asia Pacific Region 115
North America Region 116
Europe Region 118/119
Middle-East Region 120/121
Latin America Region 122/123
12:45-14:00 Inter-regional Meeting 127/128

Sub-section Meetings




Friday, 31 October 2014


Bacteriology & Immunology  117
10:15-11:15  NAPs 111

Section Meetings

Time  Meeting Room

Friday, 31 October 2014


Tuberculosis section  111
Adult & Child Lung Health 113
HIV Section 114
Tobacco Control Section 115



Technical Exhibition


There will be a Scientific and Technical Exhibition during the conference showcasing a variety of companies, agencies, non-governmental organisations (NGOs), health organisations and manufacturers of materials and equipment.